Skip to content
OpenCapital
Get started

Indivior Pharmaceuticals, Inc. INDV Earnings yield

Earnings yield at other companies

Alkermes logo
AlkermesALKS
2.6%-4.0pp
JAN
Janus Living JAN
-9.9%-4.5pp

Other financials

Income statement

See full
Revenue$317.0M+19.2%
Gross profit$277.0M+24.8%
Operating income$137.0M+108%
Net income$89.0M+89.4%
EPS (diluted)$0.69+81.6%

Balance sheet

See full
Cash & equivalents$175.0M-53.0%
Total debt$509.0M+37.6%
Total equity-$144.0M+49.5%
Total assets$1.2B-12.9%

Cash flow

See full
Operating cash flow-$9.0M-112%
CapEx$20.0M+300%
Free cash flow-$29.0M-141%

Valuation

See full
Market cap$4.53B+213%

Profitability

See full
Gross margin81.3%+1.5pp
Operating margin25.8%+23.3pp
Net margin19.4%+18.9pp
FCF margin-14.9%—

Returns & leverage

See full
Current ratio0.9×0.0×

Where this comes from

Calculated from Indivior Pharmaceuticals, Inc. ’s reported figures.

net income/market cap=6.8%

Based on trailing twelve months.

The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Indivior Pharmaceuticals, Inc. 's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Indivior Pharmaceuticals, Inc. 's earnings yield?
Indivior Pharmaceuticals, Inc. (INDV) reported earnings yield of 6.8% in Q1 2026.
How has Indivior Pharmaceuticals, Inc. 's earnings yield changed year-over-year?
Indivior Pharmaceuticals, Inc. 's earnings yield increased by 1246.3% year-over-year, from -0.6% to 6.8%.
What is the long-term trend for Indivior Pharmaceuticals, Inc. 's earnings yield?
Over 2 years (2023 to 2025), Indivior Pharmaceuticals, Inc. 's earnings yield has grown at a -12.9% compound annual growth rate (CAGR), from -6.1% to 4.7%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.